Primary Outcome Measures
Determining whether DBT-TOBI total hemoglobin concentration measurements before cycle 3 of chemotherapy can predict pathological complete response (pCR) versus non-complete responses in breast cancer. [Time Frame: 4 to 6 months] [Designated as safety issue: ]
Secondary Outcome Measures
Determining the predictive performance of early DBT-TOBI scans before the 3rd cycle of chemotherapy in distinguishing pCR versus non-pCR based on changes in tissue hemoglobin oxygen saturation. [Time Frame: 4-6 months] [Designated as safety issue: ]
Determining whether other optical parameters measured by DBT-TOBI are predictive of the final pathologic response after neoadjuvant therapy. [Time Frame: 4-6 months] [Designated as safety issue: ]
Determining whether DBT-TOBI total hemoglobin concentration measurements before the cycle 2 and after changing chemotherapy can predict pathological complete response (pCR) versus non-complete responses in breast cancer. [Time Frame: 4-6 months] [Designated as safety issue: ]
To investigate the ability of DBT-TOBI measurements to predict Residual Cancer Burden (RCB) groups 0 and 1 versus 2 and 3. [Time Frame: 4-6 months] [Designated as safety issue: ]
To investigate whether compression response-based optical property metrics are associated with lesion stiffness as measured by Magnetic Resonance Elastography. [Time Frame: 4-6 months] [Designated as safety issue: ]
To assess the threshold values for detecting pathologic Complete Response (pCR) versus non-PCR and Residual Cancer Burden (RCB) 0/1 versus RCB 2/3, respectively, for changes in optical parameters at standard time points. [Time Frame: 4-6 months] [Designated as safety issue: ]
To assess the threshold values for detecting pCR vs. non-PCR and RCB 0/1 versus RCB 2/3, respectively, for changes in MR derived tumor morphology from baseline to just prior the 3rd therapy cycle. [Time Frame: 4-6 months] [Designated as safety issue: ]
To compare the predictive abilities between the Receiver Operator Curve (ROC) developed using DBT-TOBI and MR derived tumor morphology measurements to determine which measure more accurately predicts pathologic response. [Time Frame: 4-6 months] [Designated as safety issue: ]